z-logo
open-access-imgOpen Access
Optimal Treatment for Patients with Oligometastatic Prostate Cancer
Author(s) -
Bülent Çetin,
Chiara A. Wabl,
Özge Gümüşay
Publication year - 2021
Publication title -
urologia internationalis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.771
H-Index - 53
eISSN - 1423-0399
pISSN - 0042-1138
DOI - 10.1159/000519386
Subject(s) - medicine , prostate cancer , prostatectomy , radiation therapy , oncology , prostate , disease , cancer
Oligometastatic prostate cancer (PCa) can be defined as cancer with a limited number of metastases, typically fewer than 5 lesions, and involves lesions contained within the axial versus the appendicular skeleton. Patients can present with de novo oligometastatic, oligorecurrent, or oligoprogressive PCa. Oligometastatic PCa patients demonstrate considerable improvements in survival outcomes, with a better prognosis than patients with extensive metastatic disease. However, the management of patients that present with nonsymptomatic oligometastatic PCa remains difficult. In the oligometastatic setting, the benefit of local therapies such as prostatectomy and radiotherapy on survival outcomes is an intriguing topic; however, their impact on oncological outcomes is still unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here